Posted by Michael Wonder on 21 Nov 2018
GSK retains leading position on access to medicines list
21 November 2018 - GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
The 2018 Access to Medicine Index - which measures the performance of the top 20 pharma companies across seven different categories, such as access-to-medicine management, R&D and pricing - also saw Novartis move into second place, ahead of Johnson & Johnson and Merck KGaA, while Takeda jumped 10 places to take the fifth spot.
"We are pleased to have ranked first and improved our score in the Access to Medicine Index. We welcome the recognition for having the largest proportion of our R&D pipeline dedicated to priority diseases and for the creation of an integrated Global Health R&D unit to stimulate collaboration,” said Phil Thomson, president of Global Affairs at GSK.
